- Press Releases
- Notices
Press Releases To List
-
- Dec.08.2023R & D
- Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary Endpoint
-
- Dec.06.2023R & D
- U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
-
- Dec.01.2023Corporate
- Ono Expands Investment in Ono Venture Investment Fund I, L.P. to US$200 Million
-
- Dec.01.2023Management / Finance
- Ono Announces Status of Acquisition of Own Shares
-
- Nov.24.2023R & D
- ONO Receives Supplemental Approval of Opdivo® in Japan for Expanded Use for Treatment of Malignant Mesothelioma (Excluding Malignant Pleural Mesothelioma)
Notices To List
-
- Sep.26.2023Corporate
- Corporate Report 2023 has been released.
-
- Jun.23.2023Corporate
- Voting Results (Extraordinary Report) of the 75th Ordinary General Shareholders’ Meeting
-
- Jun.22.2023Corporate
- Notice to Resolutions Passed at The 75th Ordinary General shareholders’ Meeting
-
- May.25.2023Corporate
- Notice to Convene the 75th Ordinary General Shareholders' Meeting
-
- Sep.22.2022Corporate
- Announcement on posting of Corporate Report 2022
About
We Want to Deliver New Drugs
to the World with a Wish.
For more than 300 years since its foundation in 1717, working for people’s health.
Diseases still unconquered. Patients' wishes still unfulfilled.
ONO, with a wish to meet these medical needs, devotes all its efforts to drug discovery.
